Your browser doesn't support javascript.
loading
Reversal of Peripheral Iris Depigmentation Associated with Vogt-Koyanagi-Harada Disease.
Tobaigy, Mohannad F; AlBloushi, Abdulrahman F; Al-Dhibi, Hassan A.
Afiliação
  • Tobaigy MF; Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabai.
  • AlBloushi AF; Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabai.
  • Al-Dhibi HA; Vitreoretinal & Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Ocul Immunol Inflamm ; : 1-5, 2023 Jan 19.
Article em En | MEDLINE | ID: mdl-36657743
ABSTRACT

OBJECTIVE:

To describe the reversal of peripheral iris depigmentation associated with Vogt-Koyanagi-Harada (VKH) disease.

METHODS:

A retrospective report of two cases.

RESULTS:

Both patients were diagnosed with a chronic recurrent VKH disease and developed bilateral peripheral iris depigmentation (BPID). The first patient is an 8-year-old girl who was treated with systemic corticosteroids, methotrexate and adjuvant rituximab infusions that induced complete remission of uveitis and reversal of peripheral iris depigmentation at the last follow-up. The second was a 6-year-old who was treated with topical and systemic corticosteroids and oral methotrexate that induced complete remission of uveitis and reversal of peripheral iris depigmentation at the last follow-up.

CONCLUSIONS:

Adequate control of uveitis associated with chronic recurrent VKH disease with appropriate immunomodulatory agents and perhaps adjuvant rituximab can reverse BPID and improve the outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article